low dose glp 1 agonist GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Overview of GLP-1 Receptor Agonists

To reduce these risks, its essential that treatments are carried out under strict medical supervision by qualified professionals

All trials analyzed the composite of 3 major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, except the lixisenatide study that considered 4-point MACE, which also included hospitalization for heart failure (Table 1).5764 Although all the studies with arGLP-1 have demonstrated cardiovascular safety (noninferiority vs

Rossignol, M., Gagnon, M

Yes, switching will be possible once these medications are approved

doi:10.1002/oby.24360